Difference between revisions of "Inflammatory myofibroblastic tumor"
Jump to navigation
Jump to search
Warner-admin (talk | contribs) m (Text replacement - ":Section editor transclusions|" to ":Editorial board transclusions|") |
m |
||
| Line 11: | Line 11: | ||
|} | |} | ||
{{TOC limit|limit=3}} | {{TOC limit|limit=3}} | ||
| + | =Guidelines= | ||
| + | ==[https://www.nccn.org/ NCCN]== | ||
| + | *''NCCN does not have guidelines at this granular level; please see [https://www.nccn.org/professionals/physician_gls/pdf/sarcoma.pdf NCCN Guidelines - Soft Tissue Sarcoma].'' | ||
=All lines of therapy= | =All lines of therapy= | ||
==Crizotinib monotherapy {{#subobject:d700c4|Regimen=1}}== | ==Crizotinib monotherapy {{#subobject:d700c4|Regimen=1}}== | ||
Revision as of 21:03, 5 September 2023
| Section editor | |
|---|---|
 |
Elizabeth J. Davis, MD Vanderbilt University Nashville, TN, USA |
Note: this is a rare cancer, see this page for more information. These are regimens tested in subtype-specific populations, please see the main soft tissue sarcoma page for other regimens.
1 regimens on this page
1 variants on this page
|
Guidelines
NCCN
- NCCN does not have guidelines at this granular level; please see NCCN Guidelines - Soft Tissue Sarcoma.
All lines of therapy
Crizotinib monotherapy
Regimen
| Study | Dates of enrollment | Evidence |
|---|---|---|
| Gambacorti-Passerini et al. 2018 (PROFILE 1013) | 2011-03 to 2013-10 | Phase 1b, fewer than 20 pts in this subgroup (RT) |
Biomarker eligibility criteria
- ALK+
References
- PROFILE 1013: Gambacorti-Passerini C, Orlov S, Zhang L, Braiteh F, Huang H, Esaki T, Horibe K, Ahn JS, Beck JT, Edenfield WJ, Shi Y, Taylor M, Tamura K, Van Tine BA, Wu SJ, Paolini J, Selaru P, Kim TM. Long-term effects of crizotinib in ALK-positive tumors (excluding NSCLC): A phase 1b open-label study. Am J Hematol. 2018 May;93(5):607-614. Epub 2018 Feb 8. link to original article link to PMC article PubMed NCT01121588